Analysis and data insight

Biopharma money raised: Jan. 1-May 21, 2026

Fri, 22 May 2026 13:00:00 -0400

Year-to-date money raised in public, private and other financings of biopharma companies.

Money raised by biopharma

Fri, 22 May 2026 13:00:00 -0400

Total raised in public, private and other financings of biopharma companies, comparing 2019-2026.

Lilly’s oral GLP-1 milestone highlights a steady April for FDA approvals

Fri, 22 May 2026 12:00:00 -0400

The U.S. FDA granted 14 approvals in April 2026, down from March’s 19 but broadly in line with the historical range for the month.

Apellis soars on Biogen deal as biopharma index trails the market

Thu, 21 May 2026 12:00:00 -0400

Biopharma stocks, as measured on the BioWorld Biopharmaceutical Index, underperformed both the Nasdaq Biotechnology Index and the Dow Jones Industrial Average through the first four months of 2026.

Sizing up an epidemic, with diagnostics and bioinformatics

Thu, 21 May 2026 10:00:00 -0400

It is not surprising that a large Ebola outbreak would be considered a public health emergency of international concern. But the current PHEIC is notable for the speed with which it was declared, speaking to the urgency of the situation. World Health Organization Director-General Tedros Adhanom Ghebreyesus declared the outbreak a PHEIC on Sunday, May 17, without first convening an emergency committee. That step is unprecedented.

Sizing up an epidemic, with diagnostics and bioinformatics

Wed, 20 May 2026 12:00:00 -0400

Biopharma deal and M&A values soar in early 2026

Tue, 19 May 2026 12:00:00 -0400

Biopharma deal value through the first four months of 2026 reached $92.98 billion, outpacing every recent year and running well ahead of 2025’s strong $79.82 billion over the same period. January and February each cleared $30 billion, while March and April totaled $18.05 billion and $13.3 billion, respectively.

Life sciences ‘sweet’ opportunity in US-China talks

Tue, 19 May 2026 12:00:00 -0400

Of all the issues that could be on the table at the talks between U.S. President Donald Trump and China President Xi Jinping, the life sciences sector is the “sweet spot” for collaboration between the two countries in a way that would benefit the world, Sen. Thom Tillis, R-N.C., said in a Brookings Institution webinar in advance of the two-day summit that starts May 14.

Bundibugyo is harsh reminder of need for broad vaccine strategies

Tue, 19 May 2026 09:00:00 -0400

On Sunday, May 17th, 2026, the World Health Organization classified the ongoing Bundibugyo ebolavirus outbreak in the Democratic Republic of Congo (DRC) as a public health emergency of international concern (PHEIC). The rapid escalation to PHEIC is due to several factors. Given the high number of cases, the outbreak has likely been going undetected for some time, and may be a “much larger outbreak than what is currently being detected and reported, with significant local and regional risk of spread,” according to the WHO statement. The outbreak appears to already have crossed the border from the DRC into Uganda at least twice. And all this is happening with a virus for which there are no approved treatments or vaccines.

Money raised by biopharma

Mon, 18 May 2026 13:00:00 -0400

Total raised in public, private and other financings of biopharma companies, comparing 2019-2026.

Med-tech M&A’s blockbuster streak continues with $19B April value

Mon, 18 May 2026 12:00:00 -0400

Med-tech M&A value through the first four months of 2026 reached $62.01 billion, the highest total for the period since 2022’s $73.58 billion and a dramatic step up from 2025’s $20.03 billion and 2024’s $5.74 billion over the same period.

Sen. Cassidy’s primary loss increases uncertainty

Mon, 18 May 2026 12:00:00 -0400

On the heels of the ouster of Marty Makary as the U.S. FDA commissioner and the serial leadership vacancies at the CDC and the FDA’s drugs and biologics centers, the government’s adherence to science took another blow May 16 when Sen. Bill Cassidy, R-La., lost the Louisiana primary, ending his bid for re-election.

Bundibugyo is harsh reminder of need for broad vaccine strategies

Mon, 18 May 2026 12:00:00 -0400

Biggest gainers and losers for May 11-15, 2026

Mon, 18 May 2026 11:00:00 -0400

The top 10 biopharma stock gainers and losers for the week.

Biopharma deal and M&A values soar in early 2026

Fri, 15 May 2026 12:00:00 -0400

USPTO doubles down on inconsistencies in dual IPR-court action

Thu, 14 May 2026 12:00:00 -0400

The U.S. Patent and Trademark Office (USPTO) is driving home its message that inter partes reviews (IPRs) are not to be used in conjunction with court action presenting “inconsistent positions” as a litigation strategy.

In the mix post-Ventyx, more NLRP3s to seize?

Wed, 13 May 2026 12:00:00 -0400

Eli Lilly and Co.’s buyout of Ventyx Biosciences Inc. for $1.2 billion at the start of the year brought to the forefront NLR family pyrin domain containing 3 (NLRP3) inhibitors on which a handful of developers have been working, and research in the space continues to roll out, as with the paper published March 26 in Nature that delved into mechanisms that rev up the NLRP3 inflammasome.

Life sciences ‘sweet’ opportunity in US-China talks

Wed, 13 May 2026 12:00:00 -0400

Kailera's record IPO headlines strong April for biopharma financings

Tue, 12 May 2026 12:00:00 -0400

Biopharma financing activity is continuing its rebound in early 2026 compared to the past several years. Total funding reached $38.66 billion in the first four months of 2026, more than doubling 2025’s $15.85 billion in the same period and also exceeding 2022 and 2023. While still below the peak years of 2021 and 2024, when financings topped $50 billion in the period, the 2026 total shows a strong recovery.

Follow-ons hit 7-year high, lead med-tech's $10B start to 2026

Tue, 12 May 2026 12:00:00 -0400

Med-tech financing activity in the first four months of 2026 reached $10.05 billion, similar to 2025’s $10.31 billion and 2022’s $10.62 billion. While below the peak years of 2019-2021, when financings were above $15 billion in the time period, total value is still above the levels seen in 2023-2024. April saw $1.51 billion raised, compared to $2.44 billion in March, $4.55 billion in February and $1.52 billion in January.

Biggest gainers and losers for May 4-8, 2026

Mon, 11 May 2026 11:00:00 -0400

The top 10 biopharma stock gainers and losers for the week.

BioWorld and Nasdaq stock indices

Fri, 08 May 2026 13:00:00 -0400

These graphs compare the performance of the biotech stocks for all of 2026 using the BioWorld Stock Indicator and the Nasdaq Biotech Index.

Biopharma money raised: Jan. 1-May 7, 2026

Fri, 08 May 2026 13:00:00 -0400

Year-to-date money raised in public, private and other financings of biopharma companies.

Money raised by biopharma

Fri, 08 May 2026 13:00:00 -0400

Total raised in public, private and other financings of biopharma companies, comparing 2019-2026.

Biopharma money raised by month in 2026 (US$M)

Fri, 08 May 2026 12:25:00 -0400

Biopharma money raised to-date and by month in 2026, including public, private and other financings.

Follow-ons hit 7-year high, lead med-tech's $10B start to 2026

Fri, 08 May 2026 12:00:00 -0400

Budo judo moves aplenty for Climb in autoimmune

Fri, 08 May 2026 12:00:00 -0400

Climb Bio Inc. outlined May 5 an enticing data spill ahead this year with Fc-enhanced monoclonal antibody budoprutug (budo) in autoimmune diseases. Mizuho analyst Joseph Catanzaro appreciated in his report Wellesley Hills, Mass.-based Climb’s “conviction that CD19 represents a best-in-class pan-B-cell depletion target across antibody-mediated autoimmune diseases – a relative white space for conventional mAbs.”

Hantavirus is ‘sentinel’ more than acute pandemic threat

Fri, 08 May 2026 09:00:00 -0400

News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press conference on Thursday, officials from the WHO did their best to calm the public’s fears that the MV Hondius, the ship currently heading to the Canary Islands with its remaining passengers plus assorted medical, WHO and European Center for Disease Prevention and Control staff, is the 2026 version of the Diamond Princess.

Moderna, Vir among early 2026 top infectious disease gainers

Thu, 07 May 2026 12:00:00 -0400

Infectious disease-focused biopharma stocks, tracked on the BioWorld Infectious Disease Index (BIDI), saw their collective shares roughly follow the path of broader markets like the Nasdaq Biotechnology Index (NBI) and the Dow Jones Industrial Average (DJIA) in early 2026. The BIDI ended April up 3.8%, followed by the DJIA with a 3.31% gain and 2.73% for the NBI, following a similar pattern to 2025.

Hantavirus is ‘sentinel’ more than acute pandemic threat

Thu, 07 May 2026 07:00:00 -0400